| Ticker Details |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
|
| IPO Date: |
May 28, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$31.61B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.95 | 2.30%
|
| Avg Daily Range (30 D): |
$7.81 | 3.00%
|
| Avg Daily Range (90 D): |
$6.39 | 2.25%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.57M |
| Avg Daily Volume (30 D): |
1.75M |
| Avg Daily Volume (90 D): |
1.22M |
| Trade Size |
| Avg Trade Size (Sh.): |
71 |
| Avg Trade Size (Sh.) (30 D): |
38 |
| Avg Trade Size (Sh.) (90 D): |
33 |
| Institutional Trades |
| Total Institutional Trades: |
11,363 |
| Avg Institutional Trade: |
$8.54M |
| Avg Institutional Trade (30 D): |
$14.34M |
| Avg Institutional Trade (90 D): |
$18.68M |
| Avg Institutional Trade Volume: |
.05M |
| Avg Institutional Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$16.09M |
| Avg Closing Trade (30 D): |
$60.55M |
| Avg Closing Trade (90 D): |
$62.54M |
| Avg Closing Volume: |
90.17K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$5.53
|
$1.23
|
$1.55
|
|
Diluted EPS
|
$5.37
|
$1.21
|
$1.5
|
|
Revenue
|
$4.8B
|
$1.29B
|
$1.17B
|
|
Gross Profit
|
$3.83B
|
$992.69M
|
$959.66M
|
|
Net Income / Loss
|
$733.11M
|
$164.49M
|
$205.99M
|
|
Operating Income / Loss
|
$999.78M
|
$231.44M
|
$268.64M
|
|
Cost of Revenue
|
$970.74M
|
$298.26M
|
$207.52M
|
|
Net Cash Flow
|
$593.62M
|
|
|
|
PE Ratio
|
|
|
|
|
|
|
